ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,295.30
-0.32%
Brent Oil
83.205
0.53%
Bitcoin
63,993.39
0.18%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Galmed Pharmaceuticals Ltd (GLMD)

  7. Galmed Pharmaceuticals Ltd (GLMD) News

Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GLMD
DateTimeSourceHeadlineSymbolCompany
04/04/202422:06PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023NASDAQ:GLMDGalmed Pharmaceuticals Ltd
15/03/202413:00PR Newswire (US)Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/02/202419:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
12/02/202421:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
30/11/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/11/202321:48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202321:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202321:32PR Newswire (US)Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
01/11/202320:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
26/09/202313:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
26/09/202313:30PR Newswire (US)Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/09/202321:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/09/202321:05PR Newswire (US)Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/09/202312:30Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/09/202321:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
13/09/202321:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
09/08/202321:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
09/08/202321:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
02/08/202321:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/07/202315:12Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
18/07/202314:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
18/07/202314:23Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/07/202314:44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/07/202314:30PR Newswire (US)Galmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingNASDAQ:GLMDGalmed Pharmaceuticals Ltd
13/07/202322:08Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
12/07/202322:29Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/07/202313:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/07/202313:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/07/202313:00PR Newswire (US)Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCNASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202313:41Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:GLMD

Your Recent History

LSE
CHLL
Chill Brands
LSE
AGL
Angle
LSE
SRSP
Sirius Petroleum
LSE
SCE
Surface Transforms
LSE
INSG
Insig Ai
LSE
AAZ
Anglo Asian Mining
LSE
POS
Plexus
LSE
SCLP
Scancell
LSE
AAU
Ariana Resources
LSE
SBTX
Skinbiotherapeutics
LSE
BIRD
Blackbird
LSE
GFM
Griffin Mining
LSE
HUM
Hummingbird Resources
LSE
APTA
Aptamer
LSE
LLOY
Lloyds Banking
LSE
ALBA
Alba Mineral Resources
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved